Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block

Journal of Cardiovascular Pharmacology

Volumn 44, Issue 3, 2004, Pages 278-286

  Milberg, Peter ^a   Ramtin, Shahram ^a   Mönnig, Gerold ^a   Osada, Nani ^b   Wasmer, Kristina ^a   Breithardt, Günter ^a   Haverkamp, Wilhelm ^a,c   Eckardt, Lars ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Amiodarone; Proarrhythmic potential; QT prolongation; Sotalol

Indexed keywords

AMIODARONE; POTASSIUM; SOTALOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG EFFECT; DRUG MECHANISM; HEART ARRHYTHMIA; HEART DEPOLARIZATION; HEART ELECTROPHYSIOLOGY; HEART PERFUSION; HEART REPOLARIZATION; HYPOKALEMIA; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; RABBIT; TORSADE DES POINTES;

ACTION POTENTIALS; ADMINISTRATION, ORAL; AMIODARONE; ANIMALS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; HEART BLOCK; HEART CONDUCTION SYSTEM; LONG QT SYNDROME; MALE; RABBITS; SOTALOL; TORSADES DE POINTES;

EID: 4344633215     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000129581.81508.78     Document Type: Article

References (41)

1. Eckardt L, Haverkamp W, Borggrefe M, et al. Experimental models of torsade de pointes. Cardiovasc Res. 1998;39:178-193.
2. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and pro-arrhythmia by non-anti- arrhythmic drugs: Clinical and regulatory implications: Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res. 2000;47:219-233.
3. Rosenbaum MB, Chiale PA, Halpern MS, et al. Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol. 1976;38:934-944.
4. Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation. 1999;100:2025-2034.
5. Vastesaeger M, Gillot P, Rasson G. Etude clinique dune nouvelle medication antiangoreuse. Acta Cardiologoca. 1967;2:483-500.
6. Charlier R, Delaunois G, Bauthier J, et al. [Research on the benzofuran series. XL. Anti-arrhythmic properties of amiodarone]. Cardiology. 1969; 54:83-90.
7. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med. 1994;121:529-535.
8. Jorens PG, Van Den Heuvel PA, Ranquin RE, et al. Amiodarone induced torsades de pointe. Report of three cases and review of literature. Acta Cardiol. 1989;44:411-421.
9. Mattioni TA, Zheutlin TA, Sarmiento JJ, et al. Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy. Ann Intern Med. 1989;111:574-580.
10. Kaumann AJ, Olson CB. Temporal relation between long-lasting after-contractions and action potentials in cat papillary muscles. Science. 1968; 161:293-295.
11. Chezalviel-Guilbert F, Davy JM, Poirier JM, et al. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes. JAm Coll Cardiol. 1995;26:787-792.
12. Waldo AL, Camm AJ, DeRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet. 1996;348:7-12.
13. Hondeghem LM, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation. 2001;103:2004-2013.
14. Milberg P, Eckardt L, Bruns HJ, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther. 2002;303:218-225.
15. Eckardt L, Haverkamp W, Mertens H, et al. Drug-related torsade de pointes in the isolated rabbit heart: Comparison of clofilium, d,1-Sotalol and erythromycin. J Cardiovasc Pharmacol. 1998;32:425-434.
16. Eckardt L, Breithardt G, Haverkamp W. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT-prolongation. J Pharmacol Exp Ther. 2002;300:64-71.
17. Kirchhof P, Degen H, Franz MR, et al. Amiodarone-induced postrepolarization refractoriness suppresses induction of ventricular fibrillation. J Pharmacol Exp Ther. 2003;305:257-263.
18. Eckardt L, Haverkamp W, Göttker U, et al. Divergent effect of acute ventricular dilatation on the electrophysiologic characteristics of d,1-sotalol and flecainide in the isolated rabbit heart. J Cardiovasc Electrophysiol. 1998;9:366-383.
19. Franz MR, Kirchhof PF, Fabritz CL, et al. Computer analysis of monophasic action potentials: Manual validation and clinically pertinent applications. PACE. 1995;18:1666-1678.
20. Yang T, Roden DM. Extracellular potassium modulation of drug block of I(Kr): Implications for torsade de pointes and reverse use-dependence. Circulation. 1996;93:407-411.
21. Dessertenne F. La tachycardie ventriculaire à deux foyers opposés variables. Arch Mal Coeur. 1966;59:263-272.
22. Varro A, Nakaya Y, Elharrar V, et al. The effects of amiodarone on repolarization and refractoriness of cardiac fibers. Eur J Pharmacol. 1988; 154:11-18.
23. Singh BN. Antiarrhythmic actions of amiodarone: A profile of a paradoxical agent. Am J Cardiol. 1996;41-53.
24. Hondeghem LM, Lu HR, van Rossem K, et al. Detection of proarrhythmia in the female rabbit heart: blinded validation. J Cardiovasc Electrophysiol. 2003;14:287-294.
25. Sanguinetti MC, Jurkiewicz NK. Two components of cardiac delayed rectifier K+ current: differential sensitivity to block by class III antiarrhythmic agent. J Gen Physiol. 1990;96:99-106.
26. Kamiya K, Nishiyama A, Yasui K, et al. Short- and long-term effects of amiodarone on the two components of cardiac delayed rectifier K(+) current. Circulation. 2001;103:1317-1324.
27. Sato R, Koumi S, Singer DH, et al. Amiodarone blocks the inward rectifier potassium channel in isolated guinea pig ventricular cells. J Pharmacol Exp Ther. 1994;269:1213-1219.
28. Varro A, Virag L, Papp JG. Comparison of the chronic and acute effects of amiodarone on the calcium and potassium currents in rabbit isolated cardiac myocytes. Br J Pharmacol. 1996;117:1181-1186.
29. Mason JW, Hondeghem LM, Katzung BG. Amiodarone blocks inactivated cardiac sodium channels. Pflugers Arch. 1983;396:79-81.
30. Nattel S, Talajic M, Quantz M, et al. Frequency-dependent effects of amiodarone on atrioventricular nodal function and slow-channel action potentials: evidence for calcium channel-blocking activity. Circulation. 1987;76:442-449.
31. Polster P, Broekhuysen J. The adrenergic antagonism of amiodarone. Biochem Pharmacol. 1976;25:131-134.
32. Broekhuysen J, Charlier R, Ghislain J. Action of amiodarone on guinea-pig heart sodium and potassium activated adenosine triphosphatase. Biochem Pharmacol. 1972;21:2951-2960.
33. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation. 1990;81:686-690.
34. Sicouri S, Moro S, Litovsky S, et al. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol. 1997;8:1269-1279.
35. Huikuri HV, Yli-Mayry S. Frequency dependent effects of d-sotalol and amiodarone on the action potential duration of the human right ventricle. Pacing Clin Electrophysiol. 1992;15:2103-2107.
36. Verduyn SC, Vos MA. van-der ZJ, et al. Role of interventricular dispersion of repolarization in acquired torsade-de-pointes arrhythmias: Reversal by magnesium. Cardiovasc Res. 1997;34:453-463.
37. Zabel M, Hohnloser SH, Behrens S, et al. Differential effects of D-sotalol, quinidine, and amiodarone on dispersion of ventricular repolarization in the isolated rabbit heart. J Cardiovasc Electrophysiol. 1997;8:1239-1245.
38. Cui G, Sen L, Sager P, et al. Effects of amiodarone, sematilide, and sotalol on QT dispersion. Am J Cardiol. 1994;74:896-900.
39. van Opstal JM, Schoenmakers M, Verduyn SC, et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation. 2001;104: 2722-2727.
40. Lubic SP, Nguyen KP, Dave B, et al. Antiarrhythmic agent amiodarone possesses calcium channel blocker properties. J Cardiovasc Pharmacol. 1994;24:707-714.
41. Hondeghem LM, Hoffmann P. Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability. J Cardiovasc Pharmacol. 2003;41:14-24.